Reply to comment by Arber C, et al. on: Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland

Maria Trottmann; Eva Blozik; Marcel Hilbig; Mark Pletscher; Niklaus Meier

doi:10.57187/s.3958

Author reply to technical comment

Vol. 154 No. 10 (2024)

Reply to comment by Arber C, et al. on: Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland

Maria Trottmann
Eva Blozik
Marcel Hilbig
Mark Pletscher
Niklaus Meier

DOI: https://doi.org/10.57187/s.3958
Cite this as:: Swiss Med Wkly. 2024;154:3958
Published: 03.10.2024

Summary

No abstract available.

References

Arber C, Baerlocher G, Chalandon Y, Daskalakis Michael, Duchosal M, Fehr M, et al. Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data. Swiss Med Wkly. 2024;154:3704.doi: https://doi.org/https://doi.org/10.57187/s.3704 DOI: https://doi.org/10.57187/s.3704
Nicolopoulos K, Moshi M, Min M, Stringer D, Vreugdenburg T. The CAR T-cell therapies tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) for the treatment of B-cell acute lymphoblastic leukaemia, diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Berne: Federal Office for Public Health - HTA Report, 2024. Internet: https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/carttherapien.html
Maziarz RT, Zhang J, Yang H, Chai X, Yuan C, Schwarz E, Jakovac M, Martinez-Prieto M, Agarwal A, Degtyarev E, Tam C, Salles G. Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 26. April 2022;6(8):2536–47. DOI: https://doi.org/10.1182/bloodadvances.2021006280
Salles G, Spin P, Liu FF, Garcia J, Kim Y, Hasskarl J. Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1. Adv Ther. 2021 Jun;38(6):3266–80. doi: https://doi.org/10.1007/s12325-021-01756-0 DOI: https://doi.org/10.1007/s12325-021-01756-0

How to Cite

1.

Trottmann M, Blozik E, Hilbig M, Pletscher M, Meier N. Reply to comment by Arber C, et al. on: Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland. Swiss Med Wkly [Internet]. 2024 Oct. 3 [cited 2024 Nov. 5];154(10):3958. Available from: https://smw.ch/index.php/smw/article/view/3958

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)

Maria Trottmann, Eva Blozik, Marcel Hilbig, Daniel LoVerdi, Marcello Pedruzzi, Tina Scherer, Martina Weiss, Mark Pletscher, Niklaus Meier, Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data , Swiss Medical Weekly: Vol. 153 No. 9 (2023)
Eva Gerbier, Sereina M. Graber, Marlene Rauch, Carole A. Marxer, Christoph R. Meier, David Baud, Ursula Winterfeld, Eva Blozik, Daniel Surbek, Julia Spoendlin, Alice Panchaud, Use of drugs to treat symptoms and acute conditions during pregnancy in outpatient care in Switzerland between 2014 and 2018: analysis of Swiss healthcare claims data , Swiss Medical Weekly: Vol. 151 No. 4748 (2021)
Rahel Schneider, Daphne Reinau, Nadine Schur, Eva Blozik, Mathias Früh, Andri Signorell, Christoph R. Meier, Matthias Schwenkglenks, Drug prescription patterns, polypharmacy and potentially inappropriate medication in Swiss nursing homes: a descriptive analysis based on claims data , Swiss Medical Weekly: Vol. 149 No. 3940 (2019)
Julia Spoendlin, Eva Blozik, Sereina M. Graber, Marlene Rauch, Carole A. Marxer, Stephan Rüegg, Christoph Meier, Ursula Winterfeld, Alice Panchaud, Use of valproate in pregnancy and in women of childbearing age between 2014 and 2018 in Switzerland: a retrospective analysis of Swiss healthcare claims data , Swiss Medical Weekly: Vol. 151 No. 0102 (2021)
Stefan Neuner-Jehle, Sereina M. Graber, Ellen Keizer, Carola A. Huber, Eva Blozik, Thomas Rosemann, Oliver Senn, Time trends in general practitioners’ home visits for older patients: a retrospective cross-sectional study from Switzerland , Swiss Medical Weekly: Vol. 151 No. 2728 (2021)
Julia Spoendlin, Eva Blozik, Sereina M. Graber, Marlene Rauch, Carole A. Marxer, Stephan Rüegg, Christoph Meier, Ursula Winterfeld, Alice Panchaud, Valproate in pregnancy: authors’ reply , Swiss Medical Weekly: Vol. 151 No. 0708 (2021)
Simon Wieser, Isabelle Rüthemann, Sylvia De Boni, Klaus Eichler, Mark Pletscher, Dragana Radovanovic, Tanja Ulle, Holger Auerbach, Cost of acute coronary syndrome in Switzerland in 2008 , Swiss Medical Weekly: Vol. 142 No. 3334 (2012)
Mark Pletscher, Rafael Plessow, Klaus Eichler, Simon Wieser, Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland , Swiss Medical Weekly: Vol. 143 No. 0102 (2013)

[1] Arber C, Baerlocher G, Chalandon Y, Daskalakis Michael, Duchosal M, Fehr M, et al. Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data. Swiss Med Wkly. 2024;154:3704.doi: https://doi.org/https://doi.org/10.57187/s.3704 DOI: https://doi.org/10.57187/s.3704

[2] Nicolopoulos K, Moshi M, Min M, Stringer D, Vreugdenburg T. The CAR T-cell therapies tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) for the treatment of B-cell acute lymphoblastic leukaemia, diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Berne: Federal Office for Public Health - HTA Report, 2024. Internet: https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/carttherapien.html

[3] Maziarz RT, Zhang J, Yang H, Chai X, Yuan C, Schwarz E, Jakovac M, Martinez-Prieto M, Agarwal A, Degtyarev E, Tam C, Salles G. Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 26. April 2022;6(8):2536–47. DOI: https://doi.org/10.1182/bloodadvances.2021006280

[4] Salles G, Spin P, Liu FF, Garcia J, Kim Y, Hasskarl J. Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1. Adv Ther. 2021 Jun;38(6):3266–80. doi: https://doi.org/10.1007/s12325-021-01756-0 DOI: https://doi.org/10.1007/s12325-021-01756-0